Neyssa M Marina1, Qi Liu2, Sarah S Donaldson3, Charles A Sklar4, Gregory T Armstrong5, Kevin C Oeffinger4, Wendy M Leisenring6, Jill P Ginsberg7, Tara O Henderson8, Joseph P Neglia9, Marilyn A Stovall10, Yutaka Yasui5, R Lor Randall11, David S Geller12, Leslie L Robison5, Kirsten K Ness5. 1. Department of Pediatrics, Stanford University and Lucile Packard Children's Hospital, Palo Alto, California. 2. School of Public Health, University of Alberta, Edmonton, Alberta, Canada. 3. Depratment of Radiation Oncology, Stanford University, Stanford, California. 4. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 5. Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee. 6. Seattle Children's Hospital, Clinical Statistics, Seattle, Washington. 7. Department of Pediatric Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 8. University of Chicago, Comprehensive Cancer Center, Pediatric Oncology, Chicago, Illinois. 9. University of Minnesota/Masonic Cancer Center, Pediatrics, Minneapolis, Minnesota, Minnesota. 10. The University of Texas MD Anderson Cancer Center, Houston, Texas. 11. Department of Orthopedic Surgery, Primary Children's Hospital and Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah. 12. Montefiore Medical Center-Moses Campus and Orthopedic Surgery, Children's Hospital at Montefiore, Bronx, New York.
Abstract
BACKGROUND: Ewing sarcoma survivors (ESSs) are at increased risk for treatment-related complications. The incidence of treatment-related morbidity and late mortality with aging is unknown. METHODS: This study reports survival probabilities, estimated with the Kaplan-Meier method, and the cumulative incidence of cause-specific mortality and chronic conditions among ESSs in the Childhood Cancer Survivor Study who were treated between 1970 and 1986. Piecewise exponential models were used to estimate relative rates (RRs) and 95% confidence intervals (CIs) for these outcomes. Chronic conditions were graded with the Common Terminology Criteria for Adverse Events (version 4.03). RESULTS: Among 404 5-year ESSs (median age at last follow-up, 34.8 years; range, 9.1-54.8 years), the 35-year survival rate was 70% (95% CI, 66%-74%). Late recurrence (cumulative incidence at 35 years, 15.1%) was the most common cause of death, and it was followed by treatment-related causes (11.2%). There were 53 patients with subsequent neoplasms (SNs; cumulative incidence at 35 years, 24.0%), and 38 were malignant (14.3% at 35 years). The standardized incidence ratios were 377.1 (95% CI, 172.1-715.9) for osteosarcoma, 28.9 (95% CI, 3.2-104.2) for acute myeloid leukemia, 14.9 (95% CI, 7.9-25.5) for breast cancer, and 13.1 (95% CI, 4.8-28.5) for thyroid cancer. Rates of chronic conditions were highest for musculoskeletal (RR, 18.1; 95% CI, 12.8-25.7) and cardiac complications (RR, 1.8; 95% CI, 1.4-2.3). Thirty-five years after the diagnosis, the cumulative incidences of any chronic conditions and 2 or more chronic conditions were 84.6% (95% CI, 80.4%-88.8%) and 73.8% (95% CI, 67.8%-79.9%), respectively. CONCLUSIONS: With extended follow-up, ESSs' risk for late mortality and SNs does not plateau. Treatment-related chronic conditions develop years after therapy, and this supports the need for lifelong follow-up. Cancer 2017;123:2551-60.
BACKGROUND:Ewing sarcoma survivors (ESSs) are at increased risk for treatment-related complications. The incidence of treatment-related morbidity and late mortality with aging is unknown. METHODS: This study reports survival probabilities, estimated with the Kaplan-Meier method, and the cumulative incidence of cause-specific mortality and chronic conditions among ESSs in the Childhood Cancer Survivor Study who were treated between 1970 and 1986. Piecewise exponential models were used to estimate relative rates (RRs) and 95% confidence intervals (CIs) for these outcomes. Chronic conditions were graded with the Common Terminology Criteria for Adverse Events (version 4.03). RESULTS: Among 404 5-year ESSs (median age at last follow-up, 34.8 years; range, 9.1-54.8 years), the 35-year survival rate was 70% (95% CI, 66%-74%). Late recurrence (cumulative incidence at 35 years, 15.1%) was the most common cause of death, and it was followed by treatment-related causes (11.2%). There were 53 patients with subsequent neoplasms (SNs; cumulative incidence at 35 years, 24.0%), and 38 were malignant (14.3% at 35 years). The standardized incidence ratios were 377.1 (95% CI, 172.1-715.9) for osteosarcoma, 28.9 (95% CI, 3.2-104.2) for acute myeloid leukemia, 14.9 (95% CI, 7.9-25.5) for breast cancer, and 13.1 (95% CI, 4.8-28.5) for thyroid cancer. Rates of chronic conditions were highest for musculoskeletal (RR, 18.1; 95% CI, 12.8-25.7) and cardiac complications (RR, 1.8; 95% CI, 1.4-2.3). Thirty-five years after the diagnosis, the cumulative incidences of any chronic conditions and 2 or more chronic conditions were 84.6% (95% CI, 80.4%-88.8%) and 73.8% (95% CI, 67.8%-79.9%), respectively. CONCLUSIONS: With extended follow-up, ESSs' risk for late mortality and SNs does not plateau. Treatment-related chronic conditions develop years after therapy, and this supports the need for lifelong follow-up. Cancer 2017;123:2551-60.
Authors: Bradley J Stish; Safia K Ahmed; Peter S Rose; Carola A Arndt; Nadia N Laack Journal: Pediatr Blood Cancer Date: 2015-08-14 Impact factor: 3.167
Authors: Wendy M Leisenring; Ann C Mertens; Gregory T Armstrong; Marilyn A Stovall; Joseph P Neglia; Jennifer Q Lanctot; John D Boice; John A Whitton; Yutaka Yasui Journal: J Clin Oncol Date: 2009-04-13 Impact factor: 44.544
Authors: J Dunst; S Ahrens; M Paulussen; C Rübe; W Winkelmann; A Zoubek; D Harms; H Jürgens Journal: Int J Radiat Oncol Biol Phys Date: 1998-09-01 Impact factor: 7.038
Authors: K Nysom; K Holm; S R Lipsitz; S M Mone; S D Colan; E J Orav; S E Sallan; J H Olsen; H Hertz; J R Jacobsen; S E Lipshultz Journal: J Clin Oncol Date: 1998-02 Impact factor: 44.544
Authors: M A Tucker; G J D'Angio; J D Boice; L C Strong; F P Li; M Stovall; B J Stone; D M Green; F Lombardi; W Newton Journal: N Engl J Med Date: 1987-09-03 Impact factor: 91.245
Authors: H Jürgens; V Bier; J Dunst; D Harms; A Jobke; R Kotz; J Kühl; S Müller-Weihrich; J Ritter; M Salzer-Kuntschik Journal: Klin Padiatr Date: 1988 May-Jun Impact factor: 1.349
Authors: Leslie L Robison; Ann C Mertens; John D Boice; Norman E Breslow; Sarah S Donaldson; Daniel M Green; Frederic P Li; Anna T Meadows; John J Mulvihill; Joseph P Neglia; Mark E Nesbit; Roger J Packer; John D Potter; Charles A Sklar; Malcolm A Smith; Marilyn Stovall; Louise C Strong; Yutaka Yasui; Lonnie K Zeltzer Journal: Med Pediatr Oncol Date: 2002-04
Authors: Debra L Friedman; John Whitton; Wendy Leisenring; Ann C Mertens; Sue Hammond; Marilyn Stovall; Sarah S Donaldson; Anna T Meadows; Leslie L Robison; Joseph P Neglia Journal: J Natl Cancer Inst Date: 2010-07-15 Impact factor: 11.816
Authors: Michael W Bishop; Kirsten K Ness; Chenghong Li; Wei Liu; Deo Kumar Srivastava; Wassim Chemaitilly; Kevin R Krull; Daniel M Green; Alberto S Pappo; Leslie L Robison; Melissa M Hudson; Daniel A Mulrooney Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-06-04 Impact factor: 4.254
Authors: Neyssa M Marina; Qi Liu; Sarah S Donaldson; Charles A Sklar; Gregory T Armstrong; Kevin C Oeffinger; Wendy M Leisenring; Jill P Ginsberg; Tara O Henderson; Joseph P Neglia; Marilyn A Stovall; Yutaka Yasui; R Lor Randall; David S Geller; Leslie L Robison; Kirsten K Ness Journal: Cancer Date: 2017-08-24 Impact factor: 6.860
Authors: Choh Yeung; Anna E Gibson; Sameer H Issaq; Nobu Oshima; Joshua T Baumgart; Leah D Edessa; Ganesha Rai; Daniel J Urban; Michelle S Johnson; Gloria A Benavides; Giuseppe L Squadrito; Marielle E Yohe; Haiyan Lei; Sandy Eldridge; John Hamre; Tyrone Dowdy; Victor Ruiz-Rodado; Adrian Lita; Arnulfo Mendoza; Jack F Shern; Mioara Larion; Lee J Helman; Gordon M Stott; Murali C Krishna; Matthew D Hall; Victor Darley-Usmar; Leonard M Neckers; Christine M Heske Journal: Cancer Res Date: 2019-08-20 Impact factor: 12.701
Authors: Florencia Cidre-Aranaz; Sarah Watson; James F Amatruda; Takuro Nakamura; Olivier Delattre; Enrique de Alava; Uta Dirksen; Thomas G P Grünewald Journal: Nat Rev Dis Primers Date: 2022-10-06 Impact factor: 65.038
Authors: Kathleen I Pishas; Christina D Drenberg; Cenny Taslim; Emily R Theisen; Kirsten M Johnson; Ranajeet S Saund; Ioana L Pop; Brian D Crompton; Elizabeth R Lawlor; Franck Tirode; Jaume Mora; Olivier Delattre; Mary C Beckerle; David F Callen; Sunil Sharma; Stephen L Lessnick Journal: Mol Cancer Ther Date: 2018-07-11 Impact factor: 6.261